Qol Holdings (3034) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
21 Jul, 2026Executive summary
Net sales for the six months ended September 30, 2024, rose 40.9% year-over-year to ¥124,771 million, driven by the consolidation of DAIICHI SANKYO ESPHA and strong segment growth.
Operating profit increased 71.3% year-over-year to ¥6,096 million, and ordinary profit rose 69.2% to ¥6,220 million.
Profit attributable to owners of parent declined 35.8% year-over-year to ¥1,211 million, reflecting increased non-controlling interests and temporary expenses.
EBITDA grew 62.7% year-over-year to ¥9,941 million.
Interim net profit was ¥2,334 million, up 24.1% year-over-year.
Financial highlights
Gross profit increased to ¥19,049 million from ¥11,031 million year-over-year; gross profit margin improved to 15.3% from 12.5%.
Comprehensive income rose 49.7% year-over-year to ¥2,836 million.
Basic EPS for the period was ¥32.43, down from ¥50.80 year-over-year.
Total assets increased to ¥137,286 million from ¥117,779 million at March 31, 2024.
Net assets rose to ¥57,957 million as of September 30, 2024, with a capital adequacy ratio of 39.3%.
Outlook and guidance
Full-year net sales forecast at ¥270,000 million, with 46.2% progress as of 2Q; operating profit forecast at ¥15,000 million, 40.6% progress.
Ordinary profit forecast at ¥15,200 million (up 64.2%), and profit attributable to owners of parent at ¥5,000 million (up 2.4%).
Full-year EPS forecast at ¥133.79.
Annual dividend forecast raised to ¥34.00 per share.
Three-year medium-term plan targets FY2026 net sales of ¥300 billion and operating profit of ¥24 billion.
Latest events from Qol Holdings
- Net sales rose 40.6% and operating profit increased 55.6% on strong segment and consolidation gains.3034
Q1 202521 Jul 2026 - Record sales and profit achieved; robust outlook and higher dividends forecast.3034
Q4 202521 Jul 2026 - Record-high profit and sales driven by pharmaceutical manufacturing and DAIICHI SANKYO ESPHA.3034
Q2 202621 Jul 2026 - Record-high profit and sales driven by pharmaceutical manufacturing and BPO growth, with ROE at 12.9%.3034
Q4 202621 Jul 2026 - Record sales and operating profit achieved, but parent profit declined due to higher costs and minority interests.3034
Q3 202521 Jul 2026 - Record-high quarterly sales and profits driven by pharmacy, AG product growth, and acquisition.3034
Q1 202621 Jul 2026 - Record-high sales and profit attributable to owners, with strong segment growth and stable outlook.3034
Q3 202621 Jul 2026